AI assistant
LABCORP HOLDINGS INC. — Director's Dealing 2018
Feb 13, 2018
30237_dirs_2018-02-13_3e5ead91-0922-4f4c-bf12-0d3f2c6966b0.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: LABORATORY CORP OF AMERICA HOLDINGS (LH)
CIK: 0000920148
Period of Report: 2018-02-09
Reporting Person: Ratliff John D (CEO, Covance Drug Development)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2018-02-09 | Common Stock | M | 6100 | — | Acquired | 11530 | Direct |
| 2018-02-09 | Common Stock | F | 2132 | $168.08 | Disposed | 9398 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2018-02-09 | Restricted Stock Unit | $ | M | 6100 | Disposed | Common Stock (6100) | Direct |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 80 | Indirect |
| Common Stock | 40 | Indirect |
Footnotes
F1: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock.
F2: Stock withholding to satisfy tax withholding obligations.
F3: The reporting person is not a trustee of the irrevocable trust and disclaims beneficial ownership of the shares.
F4: The Restricted Stock Units vest in three equal annual installments beginning on 2/9/2017.
F5: This number reflects the aggregate number of Restricted Stock Units held by the reporting person.